Hydroxypropyl betacyclodextrin for monkeypox virus

Tecovirimat (ST-246), a small molecule viral inhibitor, is highly active against viruses of the orthopoxvirus genus, such as smallpox virus, cowpox virus, and monkeypox virus. Recently, several reports of unusual cases of monkeypox have been found, including the United Kingdom, Portugal, and the United States, and the role of tecovirim is becoming more and more important, as tecovirim is currently a monkeypox virus drug verified by the FDA. However, the poor solubility of tecovirimycin causes obstacles in injectable formulations, so it is currently used mainly in oral medications.

Recently, a drug development company in the United States submitted a patent application for a tecovirimat injection. The researchers of this company proved through experiments that the addition of hydroxypropyl betacyclodextrin (HPBCD) to Tecovirin can play the role of solubilizing and solubilizing starvation, improve the solubility of the active ingredient of this drug, and thus improve the bioavailability of the drug, so it can be used for injectable drugs.